KR20170056521A - 항-vasa 항체, 및 이것의 제조 및 사용 방법 - Google Patents

항-vasa 항체, 및 이것의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20170056521A
KR20170056521A KR1020177005227A KR20177005227A KR20170056521A KR 20170056521 A KR20170056521 A KR 20170056521A KR 1020177005227 A KR1020177005227 A KR 1020177005227A KR 20177005227 A KR20177005227 A KR 20177005227A KR 20170056521 A KR20170056521 A KR 20170056521A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177005227A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 티 위버
보 장
Original Assignee
오바사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오바사이언스, 인크. filed Critical 오바사이언스, 인크.
Publication of KR20170056521A publication Critical patent/KR20170056521A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020177005227A 2014-09-16 2015-09-16 항-vasa 항체, 및 이것의 제조 및 사용 방법 Withdrawn KR20170056521A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US62/051,130 2014-09-16
US201462089054P 2014-12-08 2014-12-08
US62/089,054 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
KR20170056521A true KR20170056521A (ko) 2017-05-23

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005227A Withdrawn KR20170056521A (ko) 2014-09-16 2015-09-16 항-vasa 항체, 및 이것의 제조 및 사용 방법

Country Status (26)

Country Link
US (4) US9403913B2 (https=)
EP (1) EP3194448A4 (https=)
JP (2) JP2017532953A (https=)
KR (1) KR20170056521A (https=)
CN (1) CN106573985A (https=)
AP (1) AP2017009758A0 (https=)
AU (1) AU2015317813B2 (https=)
BR (1) BR112017003263A2 (https=)
CA (1) CA2959179A1 (https=)
CL (1) CL2017000402A1 (https=)
CO (1) CO2017001724A2 (https=)
CR (1) CR20170067A (https=)
DO (1) DOP2017000050A (https=)
EA (1) EA201790236A1 (https=)
EC (1) ECSP17011262A (https=)
GT (1) GT201700036A (https=)
IL (1) IL250451A0 (https=)
MX (1) MX358243B (https=)
NI (1) NI201700022A (https=)
PE (1) PE20170667A1 (https=)
PH (1) PH12017500309A1 (https=)
SG (1) SG11201701016WA (https=)
SV (1) SV2017005393A (https=)
TN (1) TN2017000066A1 (https=)
TW (1) TW201619194A (https=)
WO (1) WO2016044436A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
WO2016044436A2 (en) * 2014-09-16 2016-03-24 Ovascience, Inc. Anti-vasa antibodies, and methods of production and use thereof
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
US12534512B2 (en) 2019-11-11 2026-01-27 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefore
CN120405134A (zh) * 2024-01-30 2025-08-01 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP1233978A4 (en) 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
AU2005245899A1 (en) 2004-05-17 2005-12-01 The General Hospital Corporation Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
CN1842540B (zh) * 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
EP1829961A4 (en) * 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd METHOD FOR THE PRODUCTION OF AN ANTIBODY USING A CELL WITH HARDENED FUCOSET TRANSPORT FUNCTION
EP2336311A4 (en) 2008-09-25 2012-07-04 Univ Tokyo Nat Univ Corp ANTIBODIES AGAINST TUNA VASA
CN102395603A (zh) * 2008-12-26 2012-03-28 国立大学法人东京大学 使用抗lgr7抗体的癌症的诊断和治疗
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
EP3498826A1 (en) 2011-04-14 2019-06-19 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
CA2847292A1 (en) * 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
JP2016503817A (ja) * 2012-12-31 2016-02-08 ディヴェロップメント センター フォー バイオテクノロジー アンチグラニュリシン抗体及びその使用方法
WO2016044436A2 (en) * 2014-09-16 2016-03-24 Ovascience, Inc. Anti-vasa antibodies, and methods of production and use thereof
AU2016206945A1 (en) * 2015-01-13 2017-08-10 President And Fellows Of Harvard College Purification of germ stem cells by targeting MRP9

Also Published As

Publication number Publication date
EA201790236A1 (ru) 2017-11-30
GT201700036A (es) 2018-12-19
US20160311929A1 (en) 2016-10-27
WO2016044436A2 (en) 2016-03-24
JP2018148915A (ja) 2018-09-27
US9403913B2 (en) 2016-08-02
CL2017000402A1 (es) 2017-11-03
US20160075797A1 (en) 2016-03-17
TN2017000066A1 (en) 2018-07-04
PE20170667A1 (es) 2017-06-06
IL250451A0 (en) 2017-03-30
PH12017500309A1 (en) 2017-07-10
US20170107299A1 (en) 2017-04-20
CA2959179A1 (en) 2016-03-24
EP3194448A2 (en) 2017-07-26
CN106573985A (zh) 2017-04-19
MX2017002390A (es) 2017-07-28
TW201619194A (zh) 2016-06-01
WO2016044436A3 (en) 2016-06-09
AP2017009758A0 (en) 2017-02-28
MX358243B (es) 2018-08-10
DOP2017000050A (es) 2018-04-15
US20180155445A1 (en) 2018-06-07
NI201700022A (es) 2017-05-04
SG11201701016WA (en) 2017-03-30
AU2015317813B2 (en) 2018-04-05
CR20170067A (es) 2017-05-10
CO2017001724A2 (es) 2017-07-19
EP3194448A4 (en) 2018-03-14
US9567404B2 (en) 2017-02-14
ECSP17011262A (es) 2017-05-31
SV2017005393A (es) 2017-06-07
BR112017003263A2 (pt) 2017-11-28
AU2015317813A1 (en) 2017-03-02
JP2017532953A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
CN117098561A (zh) Ccr8抗体及其应用
CN112424223B (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
KR20170056521A (ko) 항-vasa 항체, 및 이것의 제조 및 사용 방법
US20140242095A1 (en) Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP7766870B2 (ja) 拮抗的抗原結合タンパク質
JP6660957B2 (ja) 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
AU2017260232B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
AU2022252731B2 (en) Protein Binders For iRhom2
CN112334484A (zh) 抗-CD3ε抗体及其应用方法
CN116925233A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
CN118946588A (zh) 抗pvrig抗体、其药物组合物及用途
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
KR20230169950A (ko) Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체
JP2025524347A (ja) ガンマデルタｔ細胞受容体に結合するバリアント抗体
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
JP2022550121A (ja) Ｌｉｆに特異的な結合分子及びその使用
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
CN117247453A (zh) 抗CD19 scFv FMC63序列的单克隆抗体及其制备和应用
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
HK1236552A1 (en) Anti-vasa antibodies, and methods of production and use thereof
TW202412838A (zh) 包含結合γ-δ T細胞受體之抗體之組合物
OA18333A (en) Anti-Vasa antibodies, and methods of production and use thereof
RU2812875C1 (ru) Индуцирующий цитотоксичность терапевтический агент

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination